Top Emerging In Vitro Diagnostics Solution Companies - 2021
Molzym: Facilitating Fast and Precise Culture-Independent Diagnosis for Infectious Diseases

Top 10 Emerging In Vitro Diagnostics Solution Companies - 2021

Many factors are inciting the global in vitro diagnostics (IVD) market growth; one of the primary reasons is the upswing in the number of chronic and infectious diseases cases. Besides, an upturn in the aged population is also propelling rapid testing at the bedside considerably.

In this landscape, the technologies most heavily influenced by these trends are point-of-care (POC), molecular diagnostics, and liquid biopsy used in conjunction with in vitro diagnostics. POC technology, in particular, is becoming increasingly crucial in response to the expanding need to identify both chronic and infectious diseases rapidly. The incorporation of smart devices into POC diagnostics is significantly increasing the safety, accuracy, and user-friendliness of this technology. Biosensors are another example of newer POC testing technology that is gaining increased sensitivity as research advances. A typical example of biosensors used in POC diagnostics is the commercially-available blood glucose monitor.

Amid such trends making a wave in the in vitro diagnostic sector, it is becoming imperative for healthcare organisations to equip themselves with the latest and emerging technologies in the market. In order to assist such companies to shore up their capabilities, we have compiled this issue of MedTech Outlook. In this edition, we have listed the top 10 in vitro diagnostic solution providers and top 10 emerging in vitro diagnostic solution providers. Equipped with innovative technological capabilities, these enlisted providers are transforming the IVD landscape at the cloverleaf of various disruptive technologies. Besides, the magazine comprises insights from subject matter experts, CIOs, and CXOs on the latest industry trends, best practices, and recent innovations, and highlights their expertise. We hope this issue of MedTech Outlook helps you build the partnership you and your organisation need to foster an healthcare ecosystem driven by robust and efficient technology.

We present to you MedTech Outlook’s “Top 10 Emerging In Vitro Diagnostic Solution Providers – 2021.”

    Top Emerging In Vitro Diagnostics Solution Companies

    Molzym
    Molzym is a developer and manufacturer of innovative products for molecular microbiology and microbial pathogen diagnostics. Their product offerings range from pre-analytical kits for the enrichment and extraction of microbial DNA to analytical PCR kits with ultra-clean DNA-free reagents. MolYsis™ is Molzym’s proprietary technology of human DNA removal and targeted isolation of microbial DNA from a variety of liquid and tissue samples. Molzym’s ultra-clean PCR and real-time PCR assays, targeting the 16S/18S genes, allow detection, even at low amounts, and identification down to species level with subsequent sequencing
    AgenDx Biosciences
    AgenDx is an early stage molecular diagnostics company developing a revolutionary cost-effective molecular diagnostics platform. Our novel technology allows simple molecular diagnostic lab-quality testing. With a quick sample-to-answer in minutes, our platform is positioned to transform where and how disease is detected and treated. Our platform accommodates a wide range of nucleic-acid based tests for infectious disease, cancer, and other chronic conditions including cardiovascular disease and arthritis. Our initial focus is to prove the AgenDx technology by developing tests for aiding physician’s treatment decisions for pancreatic cancer. Our platform is designed for operation by untrained users in clinical settings near the patient. The sample is collected and inserted into a disposable cartridge. A control system automates and runs the test. Clear results will be displayed and transmitted. Our proprietary system will accommodate any biological sample, including blood, saliva, and tissue
    Cellex
    Cellex is a medical device company dedicated to innovating and developing diagnostic tests that are fast, accurate, and easy and inexpensive to use. Cellex offers QFlu Dx Test - A CE Marked In Vitro Diagnostic Intended for rapid detection of Type A and B influenza virus, the test is simple, easy-to-use, rapid (about 15 minutes), and sensitive.It is a unique rapid flu test in that it detects neither an antigen as in an immunoassay nor a nucleic acid sequence as in a molecular assay
    Lumos Diagnostics
    Lumos Diagnostics (ASX:LDX) specializes in rapid, cost-effective and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures and commercializes novel Lumos-branded POC tests that target infectious and inflammatory diseases
    Metabiomics
    Metabiomics is an early stage molecular diagnostics company that is developing in-vitro diagnostics, screening tests, and health assays that leverage breakthroughs in next-generation DNA sequencing, computational systems biology, and human microbiome sciences. Over the past 10 years, the company’s founders have developed a powerful technology platform for interrogating the human gut microbiome. We have analyzed over 5,000 clinical samples associating the microbiome with various gastrointestinal diseases in collaboration with some of the leading universities and medical institutions across the United States and Canada. With non-dilutive funding from grants and contracts, we have developed our intellectual property portfolio and built up substantial clinical evidence to support a pipeline of molecular diagnostics products and services
    Savyon Diagnostics
    Savyon Diagnostics is a member of the Gamida for Life group of companies, based in the Netherlands, which is engaged in Healthcare related operations worldwide. Savyon Diagnostics tests are based upon various immunological and molecular biology techniques (Micro Arrays, RT-PCR, ELISA, MIF, IPA, Lateral Flow etc.) and also maintains multiple patents related to these products. The company possesses the unique “know how” of producing quality core biologicals including: antigens, antibodies and nucleic acid-based probes, while using cutting edge technology to manufacture the products to the high standards that laboratories and research institutions have come to depend upon. Savyon Diagnostics is accredited with the highest international quality standards of research, development and manufacture, including ISO 13485. The company’s products are all CE-IVD certified and those products sold in the USA, China, Brazil and Australia are FDA 510(k), CFDA, ANVISA and TGA approved, respectively. Most of Savyon Diagnostics products are developed by our experienced and skilled R&D team who maintain close relationships with international key opinion leaders and academic institutions. Building on its innovative R&D capabilities
    Scanogen
    Scanogen is a molecular diagnostic company developing systems to read the biomolecular information of body fluids with the goal of improving health care. The Company has developed Single MOLecule Tethering (SMOLT), a proprietary technology for rapid and ultra-sensitive detection of biomolecules. The Company is using this technology to develop a simple-to-use and sample-to-answer diagnostic platform. Scanogen has received NIH grants totaling $9.5 million to develop its diagnostic assays and it is currently focused on two areas: Point-of-care diagnosis and bloodstream infection detection. The company is located in Baltimore, Maryland. This is a privileged location to collaborate with Johns Hopkins University and with government agencies in Washington D.C (FDA, NIH, NIST)
    Singularity Sciences
    Singularity Sciences is a group of scientists, technologists, and engineers with a revolutionary idea; modernize direct-to-consumer lab testing and put the power in the patient's hands. At Singularity Sciences, we believe the clinical diagnostic testing system is broken. We are developing a groundbreaking diagnostics device that enables patients and providers a convenient and cost effective means to test thousands of clinical samples
    Valtari Bio
    Valtari Bio is a molecular diagnostics company focused on developing a point-of-care blood test to aid clinicians in the rapid triage of suspected stroke patients. Our ReST™ (Rapid evaluation Stroke Triage) test will help clinicians with or without stroke expertise make a confident initial stroke (ischemic, hemorrhagic, and transient ischemic attack) versus no stroke (e.g. complicated migraine, bell’s palsy, vertigo, dizziness, etc.) diagnosis in ten minutes or less
    Zepto Life Technology
    Zepto Life Technology is on a mission to innovate and develop a highly-sensitive and multiplexed immunoassay and molecular diagnostics technology platform that can quickly diagnose diseases and determine medical interventions using a handheld device. The root of Zepto Life’s technology was based on the giant magnetoresistance (GMR) principle, a 2007 Nobel Prize winner in Physics. The company licensed the GMR biosensing technology from the University of Minnesota. Headquartered in St. Paul, Minnesota, Zepto Life Technology became a privately-held company in 2014. Since 2014, Zepto Life Technology has been designing and developing its proprietary Gigantic Magneto-Resistance (GMR) biosensing chips, on-chip bio-surface technology, magnetic nanoparticle immunoassay, and microfluidic technology. The scientific and engineering has since built a solid intellectual property portfolio. Zepto Life’s first product is designed to measure D-Dimer and as an aid in the diagnosis of venous thromboembolism (VTE) and in the exclusion of deep vein thrombosis (DVT) and pulmonary embolism (PE). The company is also conducting advanced development and research to potentially expand its protein biomarkers technology to include molecular diagnostics in its product portfolio

In Vitro Diagnostics Info

Q1
What Do Top In Vitro Diagnostics Solutions Do?
Top In Vitro Diagnostics Solutions support testing performed on samples such as blood, tissue, urine and swabs outside the body, usually in laboratories, hospitals or point-of-care settings. These solutions may involve instruments, reagents, assay platforms, sample preparation tools, workflow software or connected reporting systems. For healthcare organizations, the category sits close to clinical decision-making: test accuracy, turnaround time, sample integrity and result interpretation can affect diagnosis, treatment selection, infection control and patient follow-up.
Q2
Why Do Top In Vitro Diagnostics Solutions Matter Now?
It's critical for top In Vitro Diagnostics solutions because health teams must detect disease earlier, increase test volume and decrease turnaround time from collection to clinical decision, disease monitoring, molecular testing, distributed care, antimicrobial resistance, public health preparedness and other market dynamics will drive demand. Additionally, issues such as labor shortages, reimbursement challenges and quality expectations continue to stress labs and are factors in assessing in Vitro Diagnostics solutions based on ability to integrate into current capacity.
Q3
How Should Healthcare Decision-Makers Evaluate In Vitro Diagnostics Providers?
Decision-makers have to look at the width and breadth of the test menu, analytical capability, regulatory clearance status, throughput, maintenance requirements, reliability of reagents and interface with the LIMS. Also need to consider training, particularly if it's a platform that will be deployed across several sites or near the patient. Good vendors make validation, quality control, service response and documentation easier for laboratory directors, clinicians and those doing purchasing; a poor fit often shows up much later.
Q4
What Value Can In Vitro Diagnostics Solutions Create for Care Delivery?
Top in vitro diagnostics solutions create the most value when they help clinicians move faster from sample collection to clear clinical decisions. Rapid infectious disease testing can help care teams respond sooner and make timely isolation decisions. More accurate molecular assays can guide treatment selection with greater confidence. Improved sample tracking can reduce lost specimens, paperwork errors and delays caused by manual reconciliation. The impact goes beyond speed alone. Reliable diagnostics can help avoid unnecessary follow-up visits, support earlier treatment and give clinicians clearer direction when symptoms are difficult to interpret. For patients, that often means less waiting, less uncertainty and a clearer understanding of what comes next.
Q5
How Are Technology and Expertise Changing This Category?
Automation, digital connectivity and AI-assisted interpretation are reshaping diagnostics, but experienced laboratory teams still play a critical role. In real lab environments, platforms must consistently manage differences in specimen quality, calibration needs, error alerts and routine quality checks without disrupting workflow. Software can make routing, result review and disease surveillance more efficient, but clinicians and laboratory leaders still need systems they can understand, trust and confidently govern. The strongest in vitro diagnostics providers recognize that testing is not just about delivering an instrument or assay. They combine scientific expertise, reliable engineering, data management and responsive service support to help laboratories operate smoothly under everyday clinical pressures.
Q6
What Should Healthcare Organizations Prioritize When Comparing Options?
Healthcare organizations comparing Top In Vitro Diagnostics Solutions should prioritize clinical reliability, implementation fit, lifecycle cost, service coverage and reporting integration. A lower upfront price may be less attractive if reagent availability is uncertain or maintenance causes repeated downtime. Decision-makers should also look at scalability across departments, cybersecurity expectations for connected systems and the provider’s ability to support audits, staff training and software updates. The strongest choice is usually the one that protects result quality while reducing friction for the laboratory team.